NCT00003199View on ClinicalTrials.gov

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 1997

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Estrogen Receptor-negative Breast CancerEstrogen Receptor-positive Breast CancerInflammatory Breast CancerMale Breast CancerProgesterone Receptor-negative Breast CancerProgesterone Receptor-positive Breast CancerStage IIIB Breast CancerStage IV Breast Cancer
Interventions
DRUG

tamoxifen citrate

Given orally

DRUG

busulfan

Given orally

DRUG

thiotepa

Given IV

DRUG

melphalan

Given IV

BIOLOGICAL

aldesleukin

Given SC

BIOLOGICAL

sargramostim

Given SC

PROCEDURE

peripheral blood stem cell transplantation

Undergo autologous peripheral blood stem cell infusion

RADIATION

radiation therapy

May undergo radiotherapy after completion of IL-2/GM-CSF

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/Puget Sound Oncology Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00003199 - Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer | Biotech Hunter | Biotech Hunter